prednisolone/sulfacetamide ophthalmic

Action and Spectrum

Actions and Spectrum 

A corticosteroid with anti-inflammatory and immunosuppressive effects is prednisolone. It functions by lowering ocular inflammation and diminishing the immunological response. 

The primary inflammatory response in the eye is what prednisolone principally addresses. Many different ocular disorders can be successfully treated with it. It is an antibiotic that prevents bacteria from multiplying and growing by preventing them from making necessary proteins.

Drug Interaction

Adverse Reaction

Frequency not defined  

Eye discharge 

Cataract 

Eye pain 

Hypersensitivity including, skin pruritus, urticaria, rash, ocular hyperemia and visual disturbance 

Eyelid erythema 

Dizziness 

Eyelid edema 

Eye pruritus 

Eye irritation 

Black Box Warning

Black Box Warning 

There are no specific black box warnings associated with prednisolone/sulfacetamide ophthalmic drug. 

Contraindication / Caution

Contraindication/Caution: 

Contraindication: 

• People who allergic or hypersensitive to prednisolone/sulfacetamide ophthalmic, or any other component in the formulation should not use the medication.  

Caution: 

• prednisolone/sulfacetamide ophthalmic medication should be used with caution in people who have fungal eye infections since the corticosteroid component may make the infection worse. 
• sulfacetamide is an example of an antibiotic whose improper or prolonged use can result in bacterial resistance. It is important to take precautions while using this drug. 
• People with a history of ocular herpes simplex should use the prednisolone/ sulfacetamide ophthalmic medication with caution since the infection may reactivate

Pregnancy / Lactation

Pregnancy warnings:     

Pregnancy category: C 

Lactation: Excretion into human milk is unknown  

Pregnancy Categories:         

Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester. 

Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women. 

Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women. 

Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits. 

Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women. 

Category N: There is no data available for the drug under this category. 

Pharmacology

Pharmacology  

prednisolone interacts with glucocorticoid receptors in cells to provide its pharmacological actions. Various anti-inflammatory and immunosuppressive effects are brought about by this binding, which modifies gene expression. 

The bacterial enzyme dihydropteroate synthase, which is involved in the manufacture of folic acid, is inhibited by sulfacetamide ophthalmic. It inhibits bacterial growth and replication by interfering with the generation of folic acid. 

Pharmacodynamics 

T cells, B cells, and macrophages are among the immune cells active in the inflammatory response that are inhibited by prednisolone.  

sulfacetamide ophthalmic interrupts bacterial metabolism and prevents bacterial growth and replication by preventing the generation of folic acid. Various gram-positive and gram-negative bacteria frequently linked to eye illnesses are susceptible to its broad-spectrum antibacterial action. 

Pharmacokinetics 

Absorption   

prednisolone is absorbed into the ocular tissues after being administered topically to the eye. It has local therapeutic effects due to its ability to permeate the cornea and conjunctiva. 

When given topically to the eye, sulfacetamide ophthalmic is also absorbed through the ocular tissues. To get to the infection, it can pierce the cornea and conjunctiva. 

Distribution 

prednisolone may penetrate the eye’s target tissues and start acting locally to reduce inflammation. 

sulfacetamide ophthalmic can penetrate ocular tissues, where it exerts its antibacterial effects on eye-inhabiting microorganisms. 

Metabolism 

prednisolone is extensively metabolized in the liver, largely by the activity of the cytochrome P450 enzymes CYP3A4 and CYP3A5. Prednisolone’s metabolites are predominantly excreted in the urine. 

The liver is where sulfacetamide ophthalmic is largely metabolized by acetylation reactions. The urine is where the metabolites are mostly eliminated. 

Elimination and excretion 

prednisolone’s metabolites are primarily excreted by the kidneys through urine. prednisolone has a variable elimination half-life, but it usually lasts between two and four hours. 

Urinary excretion is the main method of sulfacetamide and its metabolites elimination. sulfacetamide ophthalmic has a variable elimination half-life, but it typically lasts 6 to 12 hours. 

Adminstartion

Administration 

prednisolone/sulfacetamide ophthalmic medication administration is normally done directly into the eye. 

Patient Information Leaflet

Patient information leaflet 

Generic Name: prednisolone/sulfacetamide ophthalmic 

Why do we use prednisolone/sulfacetamide ophthalmic? 

prednisolone/sulfacetamide ophthalmic medication is frequently used to treat a variety of eye disorders that involve bacterial infections and inflammation.  

To lessen ocular inflammation, prednisolone is utilised. It relieves signs of different inflammatory eye disorders, such as redness, swelling, itching, and pain. 

Inflammation of the uvea, the middle layer of the eye, is referred to as uveitis. Anterior uveitis, which affects the front of the eye, can be treated with prednisolone/sulfacetamide ophthalmic.